EP1442034A1 - Benzimidazolderivate und ihre verwendung als proteinkinase-kdr-inhibitoren - Google Patents

Benzimidazolderivate und ihre verwendung als proteinkinase-kdr-inhibitoren

Info

Publication number
EP1442034A1
EP1442034A1 EP02791892A EP02791892A EP1442034A1 EP 1442034 A1 EP1442034 A1 EP 1442034A1 EP 02791892 A EP02791892 A EP 02791892A EP 02791892 A EP02791892 A EP 02791892A EP 1442034 A1 EP1442034 A1 EP 1442034A1
Authority
EP
European Patent Office
Prior art keywords
radicals
alkyl
formula
radical
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02791892A
Other languages
English (en)
French (fr)
Inventor
Didier Babin
Alain Le-Brun
Laurence Gauzy-Lazo
Hervé Bouchard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA, Aventis Pharma SA filed Critical Rhone Poulenc Rorer SA
Publication of EP1442034A1 publication Critical patent/EP1442034A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Definitions

  • the present invention relates to new benzi idazole derivatives, their preparation process, the new intermediates obtained, their application as medicaments, the pharmaceutical compositions containing them and the new use of such benzimidazole derivatives.
  • the subject of the invention is therefore new benzimidazole derivatives endowed with inhibitory effects with respect to protein kinases.
  • the benzimidazoles of the present application can thus in particular be used for the prevention or treatment of diseases which can be modulated by the inhibition of protein kinases.
  • Such protein kinases belong in particular to the following group: EGFR, Fak, FLK-1, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, flt-1, IGF-1R, KDR, PDGFR, tie2 and VEGFR. More particularly, the protein kinase KDR is cited.
  • the protein kinase Tie-2 is also particularly cited.
  • Protein kinases are a family of enzymes that catalyze the phosphorylation of hydroxy groups of specific protein residues such as tyrosine, serine or threonine residues. Such phosphorylations can greatly modify the function of proteins; thus, protein kinases play an important role in the regulation of a wide variety of cellular processes, including in particular metabolism, cell proliferation, cell differentiation or cell survival. Among the various cellular functions in which the activity of a protein kinase is involved, certain processes represent attractive targets to treat certain diseases. As an example, mention may be made in particular of angiogenesis and control of the cell cycle, in which protein kinases can play an essential role. These processes are essential for the growth of solid tumors and other diseases.
  • Angiogenesis is the process in which new vessels are formed from already existing vessels. When necessary, the vascular system has the potential to generate a network of new vessels to maintain the proper functioning of tissues and organs.
  • Angiogenesis is a complex, multi-step process that includes activation, migration, proliferation and survival of endothelial cells.
  • angiogenesis In adults, angiogenesis is fairly limited, appearing mainly only in the repair processes after injury or endometrial vascularization (Merenmies et al., Cell Growth & Differentiation, 8, 3-10, 1997). Uncontrolled angiogenesis is however found in certain pathologies such as retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration, or cancer (solid tumors) (Folkman, Nature Med., 1, 27-31, 1995).
  • VEGF-R2 vascular endothelial growth factor receptor 2 , also known as KDR, kinase insert domain receptor, or FLK-1
  • FGF-R fibroblast growth factor receptor
  • Tie-2 vascular endothelial growth factor receptor 2
  • VEGF-R2 vascular endothelial growth factor receptor 2 , also known as KDR, kinase insert domain receptor, or FLK-1
  • FGF-R fibroblast growth factor receptor
  • VEGFRs Vascular Endothelial Growth Factor
  • the VEGFR family includes VEGFR-1 (Flt-1), VEGFR-2 (KDR) and VEGFR3 (Flt4).
  • the VEGF-R2 receptor which is expressed only in endothelial cells, binds to the angiogenic growth factor VEGF, and thus mediates a transductional signal via the activation of its intracellular kinase domain.
  • the direct inhibition of the kinase activity of VEGF-R2 makes it possible to reduce the phenomenon of angiogenesis in the presence of exogenous VEGF (Strawn et al., Cancer Research, 56, 3540-3545, 1996), a process demonstrated in particular in using VEGF-R2 mutants (Millauer et al., Cancer Research, 56, 1615-1620, 1996).
  • the VEGF-R2 receptor seems to have no other function in adults than that linked to the angiogenic activity of VEGF.
  • a selective inhibitor of VEGF-R2 kinase activity should only demonstrate little toxicity.
  • KDR inhibitors therefore constitute in particular anti-angiogenic agents.
  • Angiogenesis inhibitors could thus be used in the first line against the emergence or regrowth of malignant tumors.
  • the inhibition or regulation of VEGFR-2 (KDR) therefore provides a powerful new mechanism of action for the treatment of a large number of solid tumors
  • the present application thus particularly relates to new inhibitors of the VEGFR-2 receptor (KDR) which can be used in particular for anti-angiogenic treatment in oncology.
  • KDR VEGFR-2 receptor
  • the products of the present application as inhibitors of KDR can in particular be used for the treatment or prevention of diseases chosen from the following group: cancers among which in particular breast, colon, lung and prostate cancers, atherosclerosis, degenerative muscle diseases, obesity , conjestive heart failure, Parkinson's, depression, schizophrenia, stroke, head trauma, spinal cord injury, Alzheimer's, neuropathic pain syndrome, amyotrophic lateral sclerosis, cachexia, osteoporosis and fibrotic diseases of the viscera.
  • diseases chosen from the following group: cancers among which in particular breast, colon, lung and prostate cancers, atherosclerosis, degenerative muscle diseases, obesity , conjestive heart failure, Parkinson's, depression, schizophrenia, stroke, head trauma, spinal cord injury, Alzheimer's, neuropathic pain syndrome, amyotrophic lateral sclerosis, cachexia, osteoporosis and fibrotic diseases of the viscera.
  • a subject of the present invention is therefore the products of formula (I):
  • X represents C-R2 and W, Y and Z which are identical or different represent CH or CR3;
  • R5 represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocycloalkylalkyl.
  • Yl and Y2 are such that: either Yl and Y2, identical or different, represent H, alkyl, alkenyl, cycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl optionally substituted, or Yl and Y2 form together with the nitrogen atom to which they are linked an amino cyclic radical
  • Y3 and Y4 are such that: either Y3 and Y4, identical or different, represent hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl or Y3 and Y4 form together with the nitrogen atom to which they are linked a cyclic radical optionally substituted amine
  • A5 represents H or alkyl
  • a subject of the present invention is thus the products of formula (I) as defined above corresponding to formula (la): in which
  • Xa represents C-R2a and Wa, Ya and Za, which are identical or different, represent CH or CR3a;
  • R5a represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkyl-alkyl, heteroarylalkyl and heterocycloalkylalkyl, all these radicals being optionally substituted,
  • Yla and Y2a are such that: either Yla and Y2a, identical or different, represent H, alkyl, alkoxyalkyl, aryloxyalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, cycloalkyl, aryl and heteroaryl, all of these radicals being optionally substituted, or Yla and Y2a form together with l nitrogen atom to which they are linked an optionally substituted amino cyclic radical,
  • Y3a and Y4a are such that: either Y3a and Y4a, which are identical or different, represent hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl or Y3a and Y4a form together with the nitrogen atom to which they are linked an amino cyclic radical,
  • A5 represents H or alkyl, all the alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl radicals contained in the above radicals being additionally optionally substituted by one or more radicals chosen from halogen atoms, hydroxyl, cyano, alkyl radicals , alkoxy, acylamino
  • NY3aY4a the latter radicals containing alkyl, aryl and heteroaryl being themselves optionally substituted by one or more radicals chosen from halogen atoms and alkyl, alkoxy, free, salified or esterified carboxy radicals and acylamino NH-C radicals ( 0) R6a, the phenyl radicals being additionally optionally substituted by a dioxol radical, R6a is chosen from the values of R5a, n represents an integer from 0 to 2 said products of formula (la) being in all the isomeric forms possible racemics, enantiomers and diastereoisomers, as well as addition salts with mineral and organic acids or with mineral bases.
  • a subject of the present invention is therefore the products of formula (I):
  • X represents C-R2 and W, Y and Z which are identical or different represent CH or CR3;
  • R5 represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocycloalkylalkyl.
  • R6 represents H and C1-C4 alkyl
  • n represents an integer from 0 to 2
  • Y3 and Y4 are such that: either Y3 and Y4 identical or different represent hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl or Y3 and Y4 form together with the nitrogen atom to which they are linked an amino
  • RI can comprise one, two or three substituents represented by XI, X2 and X3.
  • alkyl radical designates the radicals, linear and optionally branched, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl , isopentyl, hexyl, isohexyl and also heptyl, octyl, nonyl and decyl as well as their isomers of linear or branched position
  • hydroxyalkyl radical denotes the alkyl radicals indicated above substituted by at least one hydroxyl radical
  • alkenyl denotes radicals linear or branched containing at most 10 carbon atoms and containing one or more double bonds: mention may in particular be made of vinyl, 1-
  • NH (alk) and N (alk) (alk) have the meanings indicated above - the term halogen atom denotes chlorine, bromine, iodine or fluorine atoms and preferably the chlorine, bromine or fluorine atom,
  • aryl and heteroaryl denote saturated, carbocyclic and heterocyclic radicals containing one or more heteroatoms, monocyclic or bicyclic containing at most 12 links, the term carbocyclic or heterocyclic radical containing at most 12 links, saturated or unsaturated, containing one or more identical or different heteroatoms chosen from 0, N, NH or S, and which may contain a -C (0) link, groups together the definitions which follow:
  • unsaturated carbocyclic radical denotes in particular a cycloalkyl radical
  • cycloalkyl radical denotes the cyclo-propyl, cyclobutyl, cyclopentyl and cyclohexyl radicals and very particularly the cyclopentyl and cyclohexyl radicals,
  • monocyclic heterocyclic radical denotes a saturated or unsaturated radical consisting of 5 or 6 links such that one or more of the links represents an oxygen, sulfur or nitrogen atom: such a heterocyclic or heterocycloalkyl radical thus denotes a carbocyclic radical interrupted by one or more heteroatoms chosen from oxygen, nitrogen or sulfur atoms, it being understood that heterocyclic radicals can contain one or more heteroatoms chosen from oxygen, nitrogen or sulfur atoms and that when these heterocyclic radicals have more than one heteroatom, the heteroatoms of these heterocyclic radicals can be the same or different.
  • bicyclic heterocyclic radical denotes a saturated (heteroaryl) or unsaturated radical consisting of 8 to 12 members such that one or more of the members represents an oxygen, sulfur or nitrogen atom and in particular condensed heterocyclic groups containing at least one heteroatom chosen from sulfur, nitrogen and oxygen, for example benzothienyl such as 3-benzothienyl, benzothiazolyl, quinolyl, isoquinolyl, tetralone, benzofuryl, dihydrobenzofuran, ethylenedioxyphenyl, thyrinylphenyl , benzimidazolyle, benzoxazolyle, thionaphthyle, indolyle, purinyle, indazolyle, thienopyrazol yl, tetrahydro-indazolyl, tetrahydrocycl
  • a carbocyclic radical containing a -C (O) link is for example the tetralone radical.
  • alkylphenyl denotes a phenyl radical substituted by one or more alkyl radicals as defined above linear or branched preferably containing at most 4 carbon atoms.
  • the carboxy radical (s) of the products of formula (I) can be salified or esterified by various groups known to those skilled in the art, among which there may be mentioned, for example:
  • mineral bases such as, for example, an equivalent of sodium, potassium, lithium, calcium, magnesium or ammonium or organic bases such as, for example, methylamine, propylamine, trimethylamine, diethylamine, triethylamine, N, N-dimethylethanolamine, tris (hydroxymethyl) amino methane, ethanolamine, pyridine, picoline, dicyclohexylamine, morpholine, benzylamine, procaine, lysine , arginine, histidine, N-methylglucamine, - among the esterification compounds, alkyl radicals to form alkoxy carbonyl groups such as, for example, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl or benzyloxycarbonyl, these alkyl radicals may be substituted by radicals chosen, for example, from halogen atoms, hydroxyl, alkoxy, acyl, acyloxy, alky
  • the addition salts with mineral or organic acids of the products of formula (I) can be, for example, the salts formed with hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, propionic, acetic, trifluoroacetic, formic acids, benzoic, maleic, fumaric, succinic, tartaric, citric, oxalic, glyoxylic, aspartic, ascorbic, alkylmonosulfonic acids such as for example methanesulfonic acid, ethanesulfonic acid, propanesulfonic acid, such as for example l methanedisulfonic acid, alpha acid, beta-ethanedisulfonic acid, arylmonosulfonic acids such as benzenesulfonic acid and aryldisulfonic acids.
  • stereoisomerism can be defined in its broad sense as the isomerism of compounds having the same developed formulas, but the different groups of which are arranged differently in space, such as in particular in monosubstituted cyclohexanes whose substituent can be in axial or equatorial position, and the different possible rotational conformations of ethane derivatives.
  • stereoisomerism due to the different spatial arrangements of substituents attached, either on double bonds or on rings, which is often called geometric isomerism or cis-trans isomerism.
  • stereoisomers is used in the present application in its broadest sense and therefore relates to all of the compounds indicated above.
  • a subject of the present invention is therefore the products of formula (I) as defined above corresponding to formula (la): in which :
  • Xa represents C-R2a and Wa, Ya and Za, which are identical or different, represent CH or CR3a;
  • R5a represents alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocycloalkylalkyl.
  • R6 represents H and C1-C4 alkyl
  • n represents an integer from 0 to 2
  • Y3a and Y4a are such that: either Y3a and Y4a, which are identical or different, represent hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl or Y3a and Y4a form together with the nitrogen atom to which they are linked an amino cyclic radical, A5 represents H or alkyl, said products of formula (la) being in all the possible racemic, enantiomeric and diastereoisomeric isomeric forms, as well as the addition salts with mineral and organic acids or with mineral bases.
  • a subject of the present invention is therefore the products of formula (I) as defined above corresponding to formula (IA):
  • A represents a saturated heterocyclic radical either monocyclic containing 5 or 6 links or bicyclic containing at most 10 links, these links being such that at least two of which represent a nitrogen atom and the other identical or different represent a carbon link or a heterocyclic link chosen from O, N and S, this heterocycle A being optionally substituted by one or several radicals XA1, XA2 or XA3 chosen from the values indicated in claim 1 for the radicals XI, X2 or X3,
  • Al, A2, A3 and A4, which are identical or different, are chosen from the hydrogen atom, the halogen atoms, the hydroxyl, alkyl, alkenyl, alkoxy, nitro, cyano, aryl, heteroaryl, and aryloxy, free carboxy radicals, salified, esterified by an alkyl radical or amidified by a radical NA6A7 such that either A6 and A7 identical or different are chosen from the hydrogen atom, the alkyl, alkoxyalkyl, phenoxyalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkylalkyl and heteroarylalkyle possibly susbtitués, that is to say A6 and A7 form together with the nitrogen atom to which they are bonded a cyclic radical containing 5 or 6 links possibly susbtitué, it being understood that two consecutive radicals among Al, A2, A3 and A4 can form with the
  • A5 represents a hydrogen atom or an alkyl radical
  • the present invention thus relates to the products of formula (I) as defined above corresponding to the formula (IAa):
  • Aa represents a pyrazolyl, triazolyl or indazolyl radical, this heterocycle Aa being optionally substituted by one or more radicals XA1, XA2 or XA3 chosen from the values indicated in claim 1 for the radicals XI, X2 or X3,
  • Ala, A2a, A3a and A4a which are identical or different, are chosen from the hydrogen atom, the halogen atoms, the hydroxyl, alkyl, alkoxy, nitro, cyano, phenyl and phenoxy radicals, free, salified carboxy, esterified with a alkyl radical or amidified by a radical NA6aA7a such that either A6a and A7a identical or different are chosen from the atom of hydrogen, the alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, thienylalkyl and pyridylalkyl radicals, either A6a and A7a form together with the nitrogen atom to which they are linked a pyrrolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, morpholino radical or piperazinyl optionally substituted on the second nitrogen atom by
  • R4a, Yla, Y2a and R6b having the values defined above and alk representing a linear or branched alkyl radical containing at most 6 carbon atoms and optionally substituted as indicated above.
  • a subject of the present invention is thus the products of formula (I) as defined above in which the substituents of said products of formula (I) have the values indicated in any one of the preceding claims and in which the aryl radicals represent phenyl and naphthyl radicals; the heteroaryl radicals represent the furyl, thienyl, benzothienyl, thianthenyl radicals; pyridyl, pyrazolyl, benzimidazolyl, benzofuran, isobenzofuran and dihydrobenzofuran; the cycloalkyl radicals represent a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl radical; the heterocycloalkyl radicals represent the hexahydropyran, piperidyl or morpholino radicals; the heterocycloalkylalkyl radicals represent the hexahydropyrannalkyl, piperidylalkyl and morpholinoal
  • A represents a saturated heterocyclic radical either monocyclic containing 5 or 6 links or bicyclic containing at most 10 links, these links being such that at least two of which represent a nitrogen atom and the other identical or different represent a carbon link or a heterocyclic link chosen from O, N and S, this heterocycle A being optionally substituted by one or more radicals XAl, XA2 or XA3 chosen from halogen atoms, alkyl, alkoxy, alkylthio or thienyl radicals optionally substituted by an alkyl radical,
  • Al, A2, A3 and A4, identical or different, are chosen from the hydrogen atom, the halogen atoms, the hydroxyl, alkyl, alkoxy, nitro, cyano, phenyl and phenoxy radicals, free, salified carboxy, esterified by an alkyl radical or amidified by a radical NA6A7 such that either A6 and A7 identical or different are chosen from the hydrogen atom, the alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl and heteroarylalkyl radicals, ie A6 and A7 form together with the nitrogen atom to which they are linked a cyclic radical containing 5 or 6 members, it being understood that two consecutive radicals from Al, A2 , A3 and A4 can form, with the benzimidazole radical to which they are attached, a carbon ring containing 5 to 6 members and one or more identical or different heteroatoms chosen from O, N and S, A5 represents
  • Ylb and Y2b together form with the nitrogen atom to which they are linked to a piperidyl, hexahydrofuran, morpholinyl or morpholinylalkyl radical,
  • Alb, A2b, A3b and A4b, identical or different, are chosen from the hydrogen atom; halogen atoms; hydroxyl radicals; alkyl; alkenyle; alkoxy; nitro; cyano; furyl; thienyl; benzothienyl; naphthyl; thianthenyl; phenyl; phenoxy and carboxy free, salified, esterified by an alkyl radical or amidified by a radical NA6bA7b such that either A6b and A7b identical or different are chosen from hydrogen and alkyl radicals; alkoxyalkyl; phenoxyalkyl; phenyl; phenylalkyl; cycloalkylalkyl; cycloalkyl; furylalkyl; naphthylalkyl; thienylalkyl; piperidylalkyl; pyridylalkyl; benzothienylalkyl; pyrazolylalkyl
  • Alb, A2b, A3b and A4b identical or different are such that two of them represent hydrogen and the other two identical or different are chosen from the hydrogen atom; halogen atoms; hydroxyl radicals; alkyl; alkenyle; -0R6b
  • n-CO-R6b nitro; cyano; furyl; thienyl; benzothienyl; naphthyl; thianthenyl; phenyl; phenoxy and carboxy free, salified, esterified by an alkyl radical or amidified by a radical NA6bA7b such that either A6b and A7b identical or different are chosen from hydrogen and alkyl radicals; alkoxyalkyl; phenoxyalkyl; phenyl; phenylalkyl; cycloalkylalkyl; cycloalkyl; furylalkyl; naphthylalkyl; thienylalkyl; piperidylalkyl; pyridylalkyl; benzothienylalkyl; pyrazolylalkyl; dihydrobenzofurannalkyl; hexahydropyranalkyl; ethylenedioxyphenylalkyl; benz
  • the present invention thus particularly relates to the products of formula (I) as defined above corresponding to the formula (IAb) in which Ab represents a pyrazolyl or indazolyl radical optionally substituted by one or more radicals chosen from atoms of halogen, alkyl, alkoxy and thienyl radicals,
  • Alb, A2b, A3b and A4b, identical or different, are chosen from the hydrogen atom; halogen atoms; hydroxyl radicals; alkyl; alkenyl optionally substituted by phenyl itself optionally substituted by one or more halogen atoms; alkoxy; nitro; cyano; furyl; thienyl optionally substituted with acyl COalk; benzothienyl; naphthyl; thianthenyl; optionally substituted phenyl and phenoxy; and free, salified carboxy, esterified by an alkyl radical or amidified by an NA6bA7b radical such that either A6b and A7b, which are identical or different, are chosen from hydrogen and alkyl radicals; alkoxyalkyl containing not more than 6 carbon atoms; phenoxyalkyl optionally substituted with acylamino NH-C (O) alk; phenyl; optionally substituted phenylalkyl;
  • the present invention thus particularly relates to the products of formula (I) as defined above corresponding to the formula (IAb) in which Ab, Alb, A2b, A3b, A4b and A5b have the meanings indicated in any one of the preceding claims, and when one of Alb, A2b, A3b and A4b represents a carboxy radical amidified by a radical NA6bA7b then either one of A6b and A7b represents a hydrogen atom or an alkyl radical and the other of A6b and A7b is chosen from the values defined for A6b and A7b, ie A6b and A7b form, together with the nitrogen atom to which they are linked, a cyclic radical containing 5 or 6 members, the other substituents of said products of formula (I) having the values indicated in any one of the preceding claims, said products of formula (IAb) being in all the possible racemic, enantiomeric and diastereoisomeric isomeric forms, as well as the addition salts with min acids
  • the present invention thus particularly relates to the products of formula (I) as defined above in which X, W, Y and Z are such that two or three of them represent CH and the others are chosen from the values of CR2 or CR3 and, where appropriate, can form a dioxol radical, R2, R3 and the other substituents of said products of formula (I) having the values defined in any one of the preceding claims, said products of formula (I) being in all the possible racemic, enantiomeric and diastereoisomeric isomeric forms, as well as the addition salts with mineral and organic acids or with mineral and organic bases of said products of formula (I).
  • the present invention thus relates in particular to the products of formula (IA) as defined above in which Al, A2, A3 and A4 are such that two or three of them represent a hydrogen atom and the others are chosen among the values of A1, A2, A3 and A4 and, where appropriate, may form a dioxol radical, the other substituents of the products of formula (IA), having the values defined in any one of the preceding claims, the said products of formula (IA) being in all the possible racemic, enantiomeric and diastereoisomeric isomeric forms, as well as the addition salts with mineral and organic acids or with mineral and organic bases of the said products of formula (IA).
  • a more particular subject of the present invention is also the products of formula (I) as defined above corresponding to the formula (IAa): in which Aa represents a pyrazolyl, triazolyl or indazolyl radical, this heterocycle Aa being optionally substituted by one or more radicals XAl, XA2 or XA3 chosen from halogen atoms, alkyl, alkoxy, alkylthio or thienyl radicals optionally substituted by a radical alkyl,
  • Ala, A2a, A3a and A4a which are identical or different, are chosen from the hydrogen atom, the halogen atoms, the hydroxyl, alkyl, alkoxy, nitro, cyano, phenyl and phenoxy radicals, free, salified carboxy, esterified with a alkyl radical or amidified by a radical NA6aA7a such that either A6a and A7a which are identical or different are chosen from the hydrogen atom, the alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, thienylalkyl and pyridylalkyl radicals, or A6a and A7a form together with the nitrogen atom to which they are linked a pyrrolidinyl, pyrazolidinyl, pyrazolinyl, piperidyl, morpholino or piperazinyl radical optionally substituted on the second nitrogen atom
  • A5a represents a hydrogen atom or an alkyl radical, the above phenyl and phenoxy radicals being optionally substituted by one or more radicals chosen from halogen atoms, hydroxyl, cyano, trifluoromethyl, trifluoromethoxy radicals, alkyl, alkoxy, amino, alkylamino, dialkylamino, phenylamino, phenylalkylamino, free, salified or esterified carboxy, dioxol, all the alkyl, alkoxy and alkylthio radicals above being linear or branched containing at most 6 carbon atoms, the said products of formula (IAa) being in all the possible racemic, enantiomeric and diastereoisomeric isomeric forms, as well as the addition salts with mineral and organic acids or with mineral and organic bases of the said products of formula (IAa).
  • a more particular subject of the present invention is the products of formula (I) as defined above in which Aa represents a pyrazolyl or indazolyl radical, the other substituents having the values indicated above or below.
  • Aa represents a pyrazole or indazole radical optionally substituted as indicated above and below,
  • Ala, A2a, A3a and A4a are chosen from the following values:
  • Ala represents hydrogen or carboxy or forms a ring with the adjacent link A2a
  • A4a represents hydrogen or carboxy or forms a ring with the adjacent link A3a
  • A2a represents a free, salified carboxy radical, esterified by an optionally substituted alkyl radical or amidified carboxy as indicated above or below,
  • A2a and A3a represent two optionally substituted alkyl radicals
  • Ab represents a pyrazolyl or indazolyl radical optionally substituted by one or more radicals chosen from halogen atoms, alkyl, alkoxy and thienyl radicals,
  • Alb, A2b, A3b and A4b are chosen from the hydrogen atom, the halogen atoms, the hydroxyl, alkyl and alkoxy radicals, nitro, cyano, phenyl and phenoxy, free, salified carboxy, esterified with a alkyl radical or amidified by a radical NA6bA7b such that either A6b and A7b identical or different are chosen from alkyl, phenyl, phenylalkyl, cycloalkylalkyl, cycloalkyl, furylalkyl, or A6b and A7b form together with the nitrogen atom to which they are linked a pyrrolidinyl, morpholino or piperazinyl radical optionally substituted on the second nitrogen atom by an alkyl radical, it being understood that two consecutive radicals from Alb, A2b, A3b and A4b can form, with the benzimidazole radical to which they are attached, a radical 4, 5-ethylene
  • A5b represents a hydrogen atom, the above phenyl and phenoxy radicals being optionally substituted by one or more radicals chosen from halogen atoms, hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino radicals, dialkylamino, phenylamino, phenylalkylamino, free, salified or esterified carboxy, all the alkyl, alkoxy and alkylthio radicals above being linear or branched containing at most 4 carbon atoms, said products of formula (IAb) being in all the isomeric forms racemic, enantiomeric and diastereoisomeric, as well as the addition salts with mineral and organic acids or with mineral and organic bases of the said products of formula (IAb)).
  • radicals chosen from halogen atoms, hydroxyl, cyano, alkyl, alkoxy, amino, alkylamino radicals, dialkylamino, phenylamino, phenyl
  • the subject of the present invention is very particularly the products of formula (I) as defined above, corresponding to the following formulas: the benzylamide of 2- (1H-indazol-3-yl) -1H-benzoimidazole-5 acid -carboxylic N-methylamide of 2- (1H-indazol-3-yl) -1H-benzoimidazole-5-carboxylic acid.
  • the present invention relates very particularly to the products of formula (I) as defined above, corresponding to the following formulas: the benzylamide of 2- (1H-indazol-3-yl) -IH- benzoimidazole-5 acid carboxylic
  • the present invention relates very particularly to the products of formula (I) as defined above, corresponding to the following formulas:
  • Another subject of the present invention is the process for preparing the products of formula (I), as defined above, characterized in that an acid of formula (D) is subjected:
  • A5 ' has the meaning indicated in claim 1 for A5 in which the possible reactive functions are optionally protected by protective groups, and RI', W ', X', Y 'and Z' have the meanings indicated above
  • products of formulas (I ') which can be products of formula (I) and which, in order to obtain or other products of formula (I), one can submit, if desired and if necessary, to the one or more of the following transformation reactions, in any order: a) an acid function esterification reaction, b) an acid function ester saponification reaction, c) an oxidation reaction of alkylthio group to sulfoxide or corresponding sulfone, d) a transformation reaction of ketone function into oxi function, e) a reduction reaction of the free or esterified carboxy function into alcohol function, f) a transformation reaction of alkoxy function into hydroxyl function, or alternatively of hydroxyl function into alkoxy function, g) an oxidation reaction of alcohol function in al
  • a more particular subject of the present invention is the process for preparing the products of formula (I) as defined above corresponding to formula (IA) characterized in that an acid of formula (D) is subjected:
  • Al ', A2', A3 'and A4' have the meanings indicated above respectively for Al, A2, A3 and A4, in which the possible reactive functions are optionally protected by protective groups, in order to obtain a product of formula (IA '): in which A5' has the meaning indicated in
  • the process described above can be carried out as indicated in the following diagrams: the reactions can be carried out according to the usual conditions known to those skilled in the art and for example according to reaction conditions indicated below.
  • A2 or A3, or else Al or A4 represent a carboxy radical
  • A2 or A3, or else Al or A4 can be converted into an amide by the conventional methods known to those skilled in the art in particular according to the conventional peptide coupling methods as indicated below.
  • XI may in particular represent H and X2 thienyl optionally substituted.
  • Al and A4 may represent H and A3 and A4 may represent alkyl.
  • the substituents R '1 to R' 4 and R ' are not necessarily only protective groups, but can also be functionalities making it possible to introduce new substituents.
  • the acid esters that constitute the products of formula (II) can be obtained if necessary from the corresponding acids according to the usual methods and in particular as indicated above.
  • Such acids can be commercial such as for example 3-carboxyindazole.
  • the radical A ′ represents in particular a pyrazolyl or indazolyl radical.
  • the oxidation reaction of the alcohols of formula (III) into corresponding aldehydes of formula (IV) can be carried out according to the usual techniques, for example using manganese dioxide or PCC chromium salts of Swern type.
  • the aldehydes of formula (IV) thus obtained are reacted with a diamine of formula (V) in particular in a solvent such as DMF at reflux in the presence of NaHSO4.
  • a solvent such as DMF at reflux in the presence of NaHSO4.
  • the formation of the pyrazolyl radical can be obtained as indicated in the diagram above, in particular by reaction of an acetylene dicarboxylate of alkyl, for example methyl, with a hydrazine.
  • acetylene dicarboxylate of alkyl for example methyl
  • a hydrazine for example a hydrazine.
  • the products of formulas (I') or (IA ') constitute or not products of formula (I) or (IA) and can give products of formula (I) or (IA), or be transformed into other products of formula (I) or (IA) by being subjected to one or more of the reactions a) to k) indicated above.
  • hydroxyl groups can be protected for example by alkyl radicals such as tert-butyl, trimethylsilyl, tert-butyldimethylsilyl, methoxymethyl, tetrahydropyrannyl, benzyl or acetyl,
  • amino groups can be protected for example by acetyl, trityl, benzyl, tert-butoxycarbonyl, BOC, benzyloxycarbonyl, phthalimido or other radicals known in the chemistry of peptides,
  • acyl groups such as the formyl group can be protected, for example, in the form of cyclic or non-cyclic ketals or thiocetals such as dimethyl or diethyl ketal or ethylene dioxy ketal, or diethylthioketal or ethylenedithioketal,
  • the acid functions of the products described above can be, if desired, amidified with a primary or secondary amine, for example in methylene chloride in the presence, for example, of 1-ethyl-3- (dimethylaminopropyl) carbodiimide hydrochloride.
  • a primary or secondary amine for example in methylene chloride in the presence, for example, of 1-ethyl-3- (dimethylaminopropyl) carbodiimide hydrochloride.
  • esters formed with easily cleavable esters such as benzyl esters or ter butyl or esters known in peptide chemistry.
  • Reactions a) to k) can be carried out, for example, as indicated below.
  • the products described above can, if desired, be the subject, on the possible carboxy functions, of esterification reactions which can be carried out according to the usual methods known to those skilled in the art.
  • Any transformations of ester functions into acid functions of the products described above can be, if desired, carried out under the usual conditions known to those skilled in the art, in particular by acid or alkaline hydrolysis, for example with sodium hydroxide or potash in an alcoholic medium such as, for example, in methanol or also with hydrochloric or sulfuric acid.
  • the saponification reaction can be carried out according to the usual methods known to those skilled in the art, such as for example in a solvent such as methanol or ethanol, dioxane or dimethoxyethane, in the presence of sodium hydroxide or potassium hydroxide.
  • a solvent such as methanol or ethanol, dioxane or dimethoxyethane
  • the possible alkylthio groups of the products described above can, if desired, be converted into the corresponding sulfoxide or sulfone functions under the usual conditions known to a person skilled in the art such as, for example, peracids such as for example acid peracetic acid or metachloroperbenzoic acid or alternatively with ozone, oxone, sodium periodate in a solvent such as for example methylene chloride or dioxane at room temperature.
  • sulfoxide function can be promoted by an equimolar mixture of the product containing an alkylthio group and of the reagent such as in particular a peracid.
  • Obtaining the sulfone function can be promoted by a mixture of the product containing an alkylthio group with an excess of the reagent such as in particular a peracid.
  • the reaction for converting a ketone function into an oxime can be carried out under the usual conditions known to a person skilled in the art, such as in particular an action in the presence of an optionally O-substituted hydroxylamine in an alcohol such as for example ethanol, at room temperature or by heating.
  • the possible free or esterified carboxy functions of the products described above can be, if desired, reduced in alcohol function by the methods known to those skilled in the art: the possible esterified carboxy functions can be, if desired, reduced in function alcohol by methods known to those skilled in the art and in particular by lithium aluminum hydride in a solvent such as, for example, tetrahydrofuran or even dioxane or ethyl ether.
  • the possible free carboxy functions of the products described above can be, if desired, reduced in alcohol function in particular by boron hydride.
  • Any alkoxy functions such as in particular methoxy of the products described above can be, if desired, transformed into a hydroxyl function under the usual conditions known to those skilled in the art, for example by boron tribromide in a solvent such as by for example methylene chloride, with pyridine hydrobromide or hydrochloride or alternatively with hydrobromic or hydrochloric acid in water or trifluoro acetic acid at reflux.
  • a solvent such as by for example methylene chloride
  • pyridine hydrobromide or hydrochloride or alternatively with hydrobromic or hydrochloric acid in water or trifluoro acetic acid at reflux.
  • the possible alcohol functions of the products described above can, if desired, be converted into an aldehyde or acid function by oxidation in the usual conditions known to a person skilled in the art such as for example by the action of manganese oxide to obtain the aldehydes or of the Jones reagent to access the acids.
  • nitrile functions of the products described above can, if desired, be transformed into tetrazolyl under the usual conditions known to those skilled in the art, such as for example by cycloaddition of a metal azide such as for example the azide sodium or a trialkyltin azide on the nitrile function as indicated in the method described in the article referenced as follows: J. Organometallic Chemistry, 33, 337 (1971) KOZIMA S. & coll.
  • reaction for converting a carbamate into urea and in particular a sulfonylcarbamate into sulfonylurea can be carried out for example at reflux of a solvent such as for example toluene in the presence of the appropriate amine. It is understood that the reactions described above can be carried out as indicated or alternatively, if necessary, according to other usual methods known to those skilled in the art.
  • the phthalimido group can be eliminated by hydrazine.
  • a list of different protective groups which can be used can be found, for example, in patent BF 2,499,995.
  • J) The products described above can, if desired, be subject to exceptication reactions, for example with a mineral or organic acid or with a mineral or organic base according to the usual methods known to a person skilled in the art: such an exceptication reaction can be carried out for example in the presence of hydrochloric acid for example or also of tartaric, citric or methane sulfonic acid, in an alcohol such as for example ethanol or methanol.
  • Any optically active forms of the products described above can be prepared by splitting the racemates according to the usual methods known to those skilled in the art.
  • the products of the invention can also thus increase the therapeutic effects of commonly used antitumor agents.
  • the products of formula (I) of the present invention therefore very particularly have antiangiogenic properties.
  • the invention therefore more particularly relates to medicaments, the products as defined by the formulas (IA), (IAa) or (IAb) said products of formulas (IA), (IAa) or (IAb) being under all possible racemic, enantiomeric and diastereoisomeric isomeric forms, as well as the addition salts with mineral and organic acids or with the pharmaceutically acceptable mineral and organic bases of said products of formula (IA), (IAa) or (IAb).
  • the subject of the invention is very particularly, as medicaments, the products described below in the examples and in particular the products corresponding to the following formulas: the benzylamide of 2- (1H-indazol-3-yl) -1H-benzoimidazole-5-carboxylic acid - the N-methylamide of 2- (1H-indazol) acid -3-yl) -1H-benzoimidazole-5-carboxylic.
  • the present invention relates very particularly as medicaments to the products of formula (I) as defined above, corresponding to the following formulas: - the benzylamide of 2- (1H-indazol-3-yl) acid - 1H-benzoimidazole-5-carboxylic acid 2- (1H-indazol-3-yl) -1H-benzoimidazole-5-carboxylic acid N-methylamide.
  • the present invention relates very particularly as medicaments to the products of formula (I) as defined above, corresponding to the following formulas: - 2- (1H-Indazol-3-yl) -lH-benzoimidazole-5- carboxylic acid 4-aminosulfonyl-benzylamide
  • the invention also relates to pharmaceutical compositions containing as active principle at least one of the products of formula (I) as defined above or a pharmaceutically acceptable salt of this product or a prodrug of this product and, where appropriate where appropriate, a pharmaceutically acceptable carrier.
  • compositions containing as active ingredient at least one of the medicaments as defined above.
  • Such pharmaceutical compositions of the present invention may also, where appropriate, contain active principles of other antimitotic drugs such as in particular those based on taxol, cis-platinum, DNA intercalating agents and others.
  • compositions can be administered by the oral route, by the parenteral route or by the local route as a topical application to the skin and the mucous membranes or by injection by the intravenous or intramuscular route.
  • compositions can be solid or liquid and can be presented in all the pharmaceutical forms commonly used in human medicine such as, for example, simple or coated tablets, pills, tablets, capsules, drops, granules, injectable preparations, ointments, creams or gels; they are prepared according to the usual methods.
  • the active ingredient can be incorporated therein into excipients usually used in these pharmaceutical compositions, such as talc, gum arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous vehicles or not, fatty substances of animal or vegetable origin, paraffinic derivatives, glycols, various agents wetting, dispersing or emulsifying, preservatives.
  • the usual dosage which varies according to the product used, the subject treated and the condition in question, can be, for example, from 0.05 to 5 g per day in adults, or preferably from 0.1 to 2 g per day.
  • Another subject of the present invention is the use of the products of formula (I) as defined above or of pharmaceutically acceptable salts of these products for the preparation of a medicament intended for the inhibition of the activity of a protein kinase.
  • the present invention also relates to the use of products of formula (I) as defined above for the preparation of a medicament intended for the treatment or prevention of a disease characterized by the dysregulation of the activity d protein kinase.
  • a medicament may in particular be intended for the treatment or prevention of a disease in a mammal.
  • the present invention also relates to the use defined above in which the protein kinase is a protein tyrosine kinase.
  • the present invention also relates to the use defined above in which the protein kinase is chosen from the following group: FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, flt-1, IGF-1R, KDR, PDGFR, tie2 and VEGFR.
  • the present invention also relates to the use defined above in which the protein kinase is KDR.
  • the present invention also relates to the use defined above in which the protein kinase is tie2.
  • the present invention also relates to the use defined above in which the protein kinase is in a cell culture.
  • the present invention also relates to the use defined above in which the protein kinase is in a mammal.
  • the present invention particularly relates to the use of a product of formula (I) as defined above for the preparation of a medicament intended for the treatment or prevention of a disease chosen from the following group: disorders proliferation of blood vessels, fibrotic disorders, ⁇ mesangial 'cell proliferation disorders, metabolic disorders, allergies, asthma, thrombosis, nervous system diseases, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration and cancers.
  • a disease chosen from the following group: disorders proliferation of blood vessels, fibrotic disorders, ⁇ mesangial 'cell proliferation disorders, metabolic disorders, allergies, asthma, thrombosis, nervous system diseases, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration and cancers.
  • a more particular subject of the present invention is the use of a product of formula (I) as defined above for the preparation of a medicament intended for the treatment or prevention of a disease chosen from the following group: blood vessel proliferation disorders, fibrotic disorders, ⁇ mesangial 'cell proliferation disorders, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration and cancers.
  • a disease chosen from the following group: blood vessel proliferation disorders, fibrotic disorders, ⁇ mesangial 'cell proliferation disorders, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration and cancers.
  • a very particular subject of the present invention is the use of a product of formula (I) as defined above for the preparation of a medicament intended for the prevention or treatment of diseases linked to uncontrolled angiogenesis, for the preparation of a medicament intended for the treatment of diseases in oncology and in particular intended for the treatment of cancers.
  • these cancers we are interested in the treatment of solid tumors, in the treatment of cancers resistant to cytotoxic agents.
  • the present invention also relates to the use of the products of formula (I) as defined above for the preparation of medicaments intended for the chemotherapy of cancers.
  • Such drugs intended for cancer chemotherapy can be used alone or in combination.
  • the products of the present application can in particular be administered alone or in combination with chemotherapy or radiotherapy or also in combination for example with other therapeutic agents.
  • Such therapeutic agents can be commonly used anti-tumor agents.
  • kinase inhibitors mention may be made of butyrolactone, flavopiridol and 2 (2-hydroxyethylamino) -6-benzylamino-9-methylpurine called olucine.
  • the present invention also relates to the products of formula (I) as defined above as KDR inhibitors.
  • the present invention also relates to the products of formula (I) as defined above as tie2 inhibitors.
  • X represents Hydrogen, halogen or alkoxy as defined above.
  • NR'R represents NY1Y2 as defined above.
  • X represents hydrogen, alkynyl or NHCOCH2PH optionally substituted.
  • a Waters FractionLynx system is used, and the separations were carried out on a Waters Symmetry column (C18, 5 ⁇ M, 19x50 mm, catalog number 186000210) eluting with a linear gradient of acetonitrile containing 0.07% TFA (v / v) in water containing 0.07% TFA (v / v), gradient passing from 5 to 95% (v / v) acetonitrile / TFA in 8 minutes, then 2 minutes at 95% acetonitrile / TFA, to a flow rate of 10 ml / min.
  • the products are injected in solution in DMSO, and collected according to the detection of their molecular weight.
  • the chemical shifts of the NMR descriptions are expressed in ppm.
  • the 2- (1H-indazol-3-yl) -1H-benzoimidazole-5-carboxylic acid benzylamide can be prepared in the following manner.
  • 2- (1H-Indazol-3-yl) -1H-benzoimidazole-5-carboxylic acid can be prepared as follows: To a solution of 1 g of 1H-indazole-3-carboxaldehyde in 10 ml of dimethylformamide are added, at a temperature close to 20 ° C., 1.3 g of metabisulfite sodium and 1.04 g of 3,4-diaminobenzoic acid. The reaction mixture is brought to reflux for 1 hour, then after cooling to a temperature in the region of 20 ° C, and dilution with dichloromethane, the mixture is filtered. The collected filtrate is concentrated under reduced pressure.
  • the methyl ester of 3-indazole-carboxylic acid can be prepared as follows:
  • 2- (1H-Indazol-3-yl) -1H-benzoimidazole-5-carboxylic acid N-methylamide can be prepared by following the procedure for the preparation of 2- (1H acid N-benzylamide -indazol-3-yl) -1H- benzoimidazole-5-carboxylic acid (example 1):
  • 2- (1H-Indazol-3-yl) -1H-benzoimidazole-5-carboxylic acid N-ethylamide can be prepared by following the procedure for the preparation of 2- (1H acid N-benzylamide -indazol-3-yl) -1H- benzoimidazole-5-carboxylic acid (example 1):
  • 2- (1H-Indazol-3-yl) -1H-benzoimidazole-5-carboxylic acid N-isopropylamide can be prepared by following the procedure for the preparation of 2- (1H acid N-benzylamide -indazol-3-yl) -1H- benzoimidazole-5-carboxylic acid (example 1):
  • 2- (1H-Indazol-3-yl) -1H-benzoimidazole-5-carboxylic acid N-phenylamide can be prepared by following the procedure for the preparation of 2- (1H acid N-benzylamide -indazol-3-yl) -1H- benzoimidazole-5-carboxylic acid (example 1):
  • 2- (1H-Indazol-3-yl) -1H-benzoimidazole-5-carboxylic acid N-phenethylamide can be prepared by following the procedure for the preparation of 2- (1H acid N-benzylamide -indazol-3-yl) -1H- benzoimidazole-5-carboxylic acid (example 1):
  • 2- (1H-Indazol-3-yl) -1H-benzoimidazole-5-carboxylic acid N-morpholinoamide can be prepared by following the procedure for the preparation of 2- (1H acid N-benzylamide -indazol-3-yl) -1H- benzoimidazole-5-carboxylic acid (example 1): From 20 mg of 2- (1H-indazol-3-yl) -1H- benzoimidazole-5-carboxylic acid and 12.5 ml of morpholine, 18.6 mg of N-morpholinoamide of 1 2- (1H-indazol-3-yl) -1H-benzoimidazole-5-carboxylic acid in the form of a pale yellow powder are obtained.
  • Example 8 N- (N '-methyl-piperazino) amide of 2- (1H-indazol-3-yl) -lH-benzoimidazole-5-carboxylic acid
  • N- (N '-methyl-piperazino) amide of 2- (1H-indazol-3-yl) -lH-benzoimidazole-5-carboxylic acid can be prepared by following the procedure for the preparation of N-benzylamide 2- (1H-indazol-3-yl) -1H-benzoimidazole-5-carboxylic acid (example 1):
  • 2- (1H-Indazol-3-yl) -1H-benzoimidazole-5-carboxylic acid N-pyrrolidinoamide can be prepared by following the procedure for the preparation of 2- (1H acid N-benzylamide -indazol-3-yl) -1H- benzoimidazole-5-carboxylic acid (example 1):
  • the 2- (1H-indazol-3-yl) -1H-benzoimidazole-5-carboxylic acid N- (isobutyl) amide can be prepared by following the procedure for the preparation of acid 2 N-benzylamide - (1H-indazol-3-yl) -1H- benzoimidazole-5-carboxylic acid (example 1):
  • N- (cyclohexylmethyl) amide of 2- (1H-indazol-3-yl) -lH-benzoimidazole-5-carboxylic acid can be prepared by following the procedure for the preparation of N benzylamide of 2- acid.
  • (1H-indazol-3-yl) -1H- benzoimidazole-5-carboxylic acid (example 1):
  • the 2- (1H-indazol-3-yl) -1H-benzoimidazole-5-carboxylic acid N- (2-furfuryl) amide can be prepared by following the procedure for the preparation of N-benzylamide.
  • N-benzyl-N-methylamide can be prepared by following the procedure for preparing the acid N-benzylamide 2- (1H-indazol-3-yl) -1H- benzoimidazole-5-carboxylic acid (example 1):
  • Example 14 The methyl ester of 2- (1H-indazol-3-yl) -3H-benzoimidazole-5-carboxylic acid
  • the 2- (1H-indazol-3-yl) -3H-benzoimidazole-5-carboxylic acid methyl ester can be prepared in the following manner:
  • a mixture of 0.1 g of 1H-indazole-3-carboxaldehyde and 113.7 mg of the methyl ester of 3,4-diamino-benzoic acid in 10 ml of nitrobenzene is brought to a temperature in the region of 145 °. C for 3 hours and 45 minutes. After cooling to a temperature in the region of 20 ° C., the reaction mixture is purified on SPE (5 g of SCX phase, conditioning and washing with methanol, extraction with a 2N ammoniacal methanol solution). The ammonia solution collected during the stall is then concentrated under reduced pressure at a temperature in the region of 40 ° C.
  • 5-bromo 2- (1H-indazol-3-yl) -3H-benzoimidazole can be prepared by following the procedure for the preparation of 5, 6-dimethyl-2- (1H-indazol-3-yl) -1H - benzoimidazole (example 15):
  • 2- (5-ethoxy-2H-pyrazol-3-yl) -lH-benzoimidazole-4-carboxylic acid can be obtained from 2- (2- benzyl-5-ethoxy-2H-pyrazol- acid) 3-yl) -1H-benzoimidazole-4-carboxylic by deprotection of the benzyl group in the presence of hydrogen and a catalyst such as palladium.
  • the methyl ester of 2-benzyl-5-hydroxy-2H-pyrazole-3-carboxylic acid can be prepared in the following manner:
  • the filtrate can be purified by flash chromatography on 400g of silica 20-45 ⁇ m (deposit in a mixture of ethyl acetate / cyclohexane 25/75; eluent ethyl acetate / cyclohexane 25/75 then 40/60) to give a batch additional methyl ester of 2-benzyl-5-hydroxy-2H-pyrazole-3-carboxylic acid in the form of a white powder.
  • 5,6-dimethyl-2- (5-methyl-2H-pyrazol-3-yl) -IH-benzoimidazole can be prepared by following the procedure described for the preparation of 5,6-dimethyl-2- (1H- indazol-3-yl) -IH-benzoimidazole (example 15):
  • 5-methyl-2H-pyrazol-3-carboxaldehyde can be prepared from the ethyl ester of commercial 5-methyl-2H-pyrazol-3-carboxylic acid by following the procedure described for the preparation of 1H- indazole-3-carboxaldehyde from the methyl ester of 3-indazole-carboxylic acid.
  • Example 21 5, 6-dimethyl-2- (5-thiophen-2-yI-2H-pyrazol-3-yl) -IH-benzoimidazole
  • 5,6-dimethyl-2- (5-thiophen-2-yl-2H-pyrazol-3-yl) -IH- benzoimidazole can be prepared by following the procedure described for the preparation of 5,6-dimethyl-2 - (1H-indazol-3-yl) -IH-benzoimidazole (example 15):
  • 5-thiophen-2-yl-2H-pyrazol-3-carboxaldehyde can be prepared from the ethyl ester of commercial 5-thiophen-2-yl-2H-pyrazol-3-carboxylic acid by following the mode procedure described for the preparation of 1H-indazole-3-carboxaldehyde from the methyl ester of 3-indazole-carboxylic acid.
  • 2- (4-bromo-2H-pyrazol-3-yl) -5,6-dimethyl-1H-benzoimidazole can be prepared by following the procedure procedure described for the preparation of 5, 6-dimethyl-2- (1H-indazol-3-yl) -IH-benzoimidazole (example 15):
  • 5-ethyl-2H- ⁇ yrazol-3-carboxaldehyde can be prepared from the ethyl ester of 5-ethyl-2H-pyrazol-3-carboxylic acid by following the procedure described for the preparation of 1H-indazole -3- carboxaldehyde from the methyl ester of 3-indazole-carboxylic acid.
  • the ethyl ester of 5-ethyl-2H-pyrazol-3-carboxylic acid can be prepared according to the general procedure of the following reference: Kunio Seki et al., Chem. Pharm. Bull., 32 (4), 1568-1577 (1984).
  • 2- (5-ethyl-2H-pyrazol-3-yl) -5-methoxy-1H-benzoimidazole can be prepared by following the procedure described for the preparation of 5, 6-dimethyl-2- (1H-indazol- 3-yl) -IH-benzoimidazole (Example 15): From 100 mg of 5-ethyl-2H-pyrazol-3-carboxaldehyde, 138 mg of 4-methoxy-1,2-phenylenediamine, and 153 mg of metabisulfite sodium, in 1 ml of ethanol and 3 ml of dimethylformamide, after purification by SPE (phase SCX, washing with methanol, extraction with 2N ammoniacal methanol), followed by reverse phase HPLC (phase C18 5 mm, dimension 100 ⁇ 25) mm, flow rate 20 ml / min, elution gradient acetonitrile / TFA 0.07% -water / TFA 0.07% from 5-95 to 95-5 (v
  • 2- (5-ethyl-2H-pyrazol-3-yl) -5-bromo-1H-benzoimidazole can be prepared by following the procedure described for the preparation of 5, 6-dimethyl-2- (1H-indazol- 3-yl) - IH-benzoimidazole (example 15): From 20 mg of 5-ethyl-2H-pyrazol-3-carboxaldehyde,
  • Examples 97 to 145 of the present application represented in the table below of FIG. 1 can be prepared according to the diagrams indicated above and in particular according to the procedures indicated below.
  • Step 1 Synthesis of 3- (6-bromo-1H-benzoimidazol-2-yl) - 2H-indazole
  • Step 2 Synthesis of 1- [2- (1-Acetyl-1H-indazol-3-yl) -5- phenyl-benzoimidazol-1-yl] -ethanone
  • Step 3 Synthesis of 3- (6-Phenyl-1H-benzoimidazol-2-yl) - 2H-indazole
  • the mixture is then diluted with 3 ml of ethyl acetate and then washed with 2 times 2 ml of water.
  • the organic phase is dried over magnesium sulfate and then concentrated to dryness under reduced pressure. 48 mg of a brown solid are then obtained which is dissolved in 500 ⁇ L of tetrahydrofuran, to which 500 ⁇ L of diethylamine are added.
  • the reaction mixture is heated at 60 ° C for 4 hours and then allowed to return to room temperature.
  • the values of Z3 and Z4 are chosen from the values of R2 and R3 as defined above and the values of Zl and -OZ2 are chosen from the values of XI, X2 or X3 with RI represents a pyrazole radical.
  • Step 1 the cyclization is carried out as described in the articles: Chem. Pharm. Bull., 31 (4), 1228-1234 (1983); J. Org. Chem., 47 (2), 214-221 (1982).
  • PPA polyphosphoric acid
  • step 4 is carried out with 15 benzyl or allyl bromides, 15 ⁇ - products bromocarbonyl and 15 acid chlorides in DMF or in NMP: the corresponding products expected from the following table which represents Examples 181 to 228 of the present application are thus obtained.
  • Example 1 is taken as an example of pharmaceutical preparation, this preparation can be carried out if desired with other products as examples in the present application.
  • the inhibitory effect of the compounds is determined in a substrate phosphorylation test by the enzyme KDR in vitro by the flasplate technique (96-well plate, NEN).
  • the cytoplasmic domain of the human KDR enzyme is cloned as a GST fusion into the baculovirus expression vector pFastBac.
  • the protein is expressed in SF21 cells and purified to approximately 60% homogeneity.
  • KDR kinase activity is measured in 20 mM MOPS, 10 mM MgC12, 10 mM MnC12, ImM DTT, 2.5 mM EGTA, 10 mM ⁇ -glycerophosphate, pH 7.2 in the presence of 10 mM MgC12, 100 ⁇ M Na3V04, 1 mM NaF . 10 ⁇ l of the compound are added to 70 ⁇ l of kinase buffer containing 100 ng of KDR enzyme at 4 ° C.
  • the reaction is started by adding 20 ⁇ l of solution containing 2 ⁇ g of substrate (fragment SH2-SH3 of PLC ⁇ expressed in the form of GST fusion protein), 2 ⁇ Ci ⁇ 33P [ATP] and 2 ⁇ M cold ATP. After 1 hour incubation at 37 ° C, the reaction is stopped by adding 1 volume
  • Radioactivity is measured in each well using a Top Count NXT instrument (Packard).
  • the background noise is determined by measuring the radioactivity in quadruplate wells containing radioactive ATP and the substrate alone.
  • An activity control is measured in quadruplate wells containing all the reagents ( ⁇ 33P- [ATP], KDR and the substrate PLC ⁇ ) and in the absence of compound.
  • the inhibition of KDR activity with the compound of the invention is expressed as a percentage of inhibition of the control activity determined in the absence of compound.
  • Compound SU5614 (Calbiochem) (1 ⁇ M) is included in each plate as an inhibition control.
  • the IC50s of the compounds are calculated after plotting the dose-response curves.
  • the IC50 corresponds to the concentration of the compound which induces 50% inhibition of kinase activity.
  • the anti-KDR activity of the molecules is evaluated by incorporation of [14C] -thymidine in HDMEC (Human Dermal Microvascular Endothelial Cell) in response to VEGF.
  • HDMEC Human Type Culture Collection (Promocell, passage 5 to 7) are seeded in 100 ⁇ l at 5000 cells per well in 96-well Cytostar (Amersham) plates precotated with attachment factor (AF, Cascad Biologics) at 37 ° C, 5% C02, on day 1. On day 2, the complete medium (basal medium supplemented with 5% FCS and a mixture of growth factors) is replaced with minimum medium (basal medium supplemented with 5% FCS) and the cells are incubated for 24 hours.
  • FCS attachment factor
  • the medium is replaced by 200 ⁇ l of new medium supplemented or not with 100 ng / ml VEGF (R&D System) and containing or not containing the compound of the invention and 0.1 ⁇ Ci [14C] -thymidine.
  • the cells are incubated at 37 ° C under 5% CO 2 for 4 days.
  • the incorporation of [14C] -thymidine is then quantified by counting the radioactivity.
  • the tests are carried out in 3 wells.
  • the final concentration of DMSO in the test is 0.1%.
  • The% inhibition is calculated as follows: [cpm (+ VEGF) - cpm (+ VEGF + cpd) / cpm (+ VEGF) - cpm (BM5% FCS)] xl00.
  • the endothelial cells are seeded at 20,000 cells per well in a 96-well plate precoated with attachment factor. After 8 hours of culture, the medium is changed and the cells are preincubated with the compounds (0.1% final DMSO) in basal medium for 16 hours. The synthesis of TF (Tissue factor) is induced by addition of VEGF (100 ng / ml final). After 6 hours of incubation, the cells are rinsed and lysed. The tissue factor is then detected using the Imubind ELISA test. 3) Effect of molecules on VEGF-independent growth of HDMEC
  • the HDMECs (5000 cells per well) are seeded in complete medium in 96-well Cytostar (Amersham) plates precoated with attachment factor (AF, Cascad Biologics) at 37 ° C, 5% C02, on day 1.
  • the complete medium is then removed and the cells are incubated in 200 ⁇ l of complete medium containing the molecules of the invention and [14C] -thymidine (0.1 ⁇ Ci).
  • the incorporation of [14C] -thymidine is measured using a Wallac counter after 3 days of incubation. The% inhibition is calculated as follows: [cpm (CM) - cpm (CM + cpd) / cpm (CM)] xl00.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP02791892A 2001-10-26 2002-10-24 Benzimidazolderivate und ihre verwendung als proteinkinase-kdr-inhibitoren Withdrawn EP1442034A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0113867 2001-10-26
FR0113867A FR2831536A1 (fr) 2001-10-26 2001-10-26 Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
PCT/FR2002/003647 WO2003035644A1 (fr) 2001-10-26 2002-10-24 Derives de benzimidazoles et_leur utilisation comme inhibiteurs de proteine kinase kdr

Publications (1)

Publication Number Publication Date
EP1442034A1 true EP1442034A1 (de) 2004-08-04

Family

ID=8868755

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02791892A Withdrawn EP1442034A1 (de) 2001-10-26 2002-10-24 Benzimidazolderivate und ihre verwendung als proteinkinase-kdr-inhibitoren

Country Status (7)

Country Link
US (2) US20050009894A1 (de)
EP (1) EP1442034A1 (de)
JP (2) JP4377228B2 (de)
CA (1) CA2466813A1 (de)
FR (1) FR2831536A1 (de)
MX (1) MXPA04003381A (de)
WO (1) WO2003035644A1 (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
EP1651631A1 (de) * 2003-08-01 2006-05-03 Genelabs Technologies, Inc. Bicyclische imidazolderivate gegen flaviviridae
PT1682553E (pt) * 2003-09-08 2010-07-29 Aventis Pharma Inc Tienopirazoles
JP4764823B2 (ja) * 2003-10-06 2011-09-07 グラクソ グループ リミテッド キナーゼ阻害剤としての１，６−二置換アザベンゾイミダゾールの調製
EP1682103A1 (de) * 2003-10-27 2006-07-26 Novartis AG Indolyl-pyrroldion-derivate zur behandlung von neurologischen und vaskulären störungen im zusammenhang mit der beta-amyloid-erzeugung und/oder aggregation
WO2005065686A1 (en) * 2004-01-07 2005-07-21 Adipogen Pharmaceuticals Pty Limited Differentiation modulating agents and uses therefor
JP2008503469A (ja) 2004-06-17 2008-02-07 ワイス ゴナドトロピン放出ホルモン受容体アンタゴニスト
CA2570693A1 (en) * 2004-06-17 2006-01-26 Wyeth Processes for preparing gonadotropin releasing hormone receptor antagonists
EP1797072A4 (de) * 2004-09-17 2009-09-09 Exelixis Inc Pyrazolkinasemodulatoren und verwendungsverfahren
JP2008520732A (ja) * 2004-11-23 2008-06-19 ワイス ゴナドトロピン放出ホルモン受容体アンタゴニスト
US20060142247A1 (en) * 2004-12-17 2006-06-29 Guy Georges Tricyclic heterocycles
EP1836199A1 (de) * 2004-12-30 2007-09-26 Astex Therapeutics Limited Die aktivität von cdk, gsk und aurora-kinasen modullierende thiazol- und isothiazolderivate
US8110573B2 (en) * 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
CN101103026A (zh) * 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
US7538113B2 (en) * 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) * 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) * 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US20060189619A1 (en) * 2005-02-24 2006-08-24 Wyeth 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds
GB0506133D0 (en) * 2005-03-24 2005-05-04 Sterix Ltd Compound
JP2008533181A (ja) * 2005-04-14 2008-08-21 エフ．ホフマン−ラ ロシュ アーゲー 三環式アゾール誘導体、それらの製造及び医薬品としての使用
WO2006118257A1 (ja) * 2005-04-28 2006-11-09 Kyowa Hakko Kogyo Co., Ltd. インダゾール-3-イルメチルホスホニウム塩の製造法
US7531542B2 (en) * 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
JP2009001495A (ja) * 2005-10-13 2009-01-08 Taisho Pharmaceutical Co Ltd ２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体
US20100056505A1 (en) * 2005-11-21 2010-03-04 Biogen Idec Ma Inc. Substituted Pyrazalones
US8399442B2 (en) 2005-12-30 2013-03-19 Astex Therapeutics Limited Pharmaceutical compounds
EP2043635A2 (de) * 2006-06-29 2009-04-08 Astex Therapeutics Limited Pharmazeutische kombinationen
EP2049119A2 (de) 2006-06-29 2009-04-22 Astex Therapeutics Limited Pharmazeutische kombinationen von 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-harnstoff
FR2903406B1 (fr) 2006-07-04 2012-08-10 Aventis Pharma Sa Derives de pyrazolylbenzimidazole,compositions les contenant et utilisation
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
DK3289876T3 (da) 2008-06-16 2022-10-10 Univ Tennessee Res Found Forbindelser til behandling af cancer
JP5758292B2 (ja) 2008-07-03 2015-08-05 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン調節薬としてのベンズイミダゾールおよび関連する類似体
WO2011017219A1 (en) * 2009-08-03 2011-02-10 The Regents Of The University Of California Imidazoquinoxalinones and anti-tumor treatment
JP5763072B2 (ja) 2009-08-10 2015-08-12 サミュメッド リミテッド ライアビリティ カンパニー Ｗｎｔシグナル経路のインダゾール阻害剤およびその治療的使用
BR112012018413A2 (pt) 2009-12-21 2016-08-09 Samumed Llc 1h-pirazol[3,4-b]piridinas e usos terapêuticos dos mesmos.
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
CA2799154A1 (en) 2010-05-12 2011-11-17 Abbvie Inc. Indazole inhibitors of kinase
AR082889A1 (es) 2011-05-09 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones para la inhibicion de nampt
PL2755483T3 (pl) 2011-09-14 2019-06-28 Samumed, Llc Indazolo-3-karboksyamidy i ich zastosowanie jako inhibitorów szlaków sygnalizacji WNT/B-kateniny
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
BR112014026305A2 (pt) 2012-04-24 2017-06-27 Chugai Pharmaceutical Co Ltd derivado de quinazolidinadiona
JP6177768B2 (ja) * 2012-04-24 2017-08-09 中外製薬株式会社 ベンズアミド誘導体
MA37577B1 (fr) 2012-05-04 2018-05-31 Samumed Llc 1h-pyrazolo[3,4-b]pyridines et leurs utilisations thérapeutiques
EP2865747B1 (de) 2012-06-25 2018-08-22 Kyowa Hakko Kirin Co., Ltd. 4,6-hexadecadien-2,4-dicarboxylsäurederivat
JP6355648B2 (ja) 2013-01-08 2018-07-11 サミュメッド リミテッド ライアビリティ カンパニー Ｗｎｔシグナル伝達経路の３−（ベンゾイミダゾール−２−イル）−インダゾール阻害剤およびそれらの治療的使用
TWI644899B (zh) 2013-02-04 2018-12-21 健生藥品公司 Ｆｌａｐ調節劑
US9079866B2 (en) 2013-02-04 2015-07-14 Janssen Pharmaceutica Nv Flap modulators
CN105163584B (zh) 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物
PL403149A1 (pl) * 2013-03-14 2014-09-15 Celon Pharma Spółka Akcyjna Nowe związki pochodne pirazolilobenzo[d]imidazolu
EP2970177A1 (de) 2013-03-15 2016-01-20 Pfizer Inc. Indolverbindungen zur ampk-aktivierung
CA2927830A1 (en) 2013-10-23 2015-04-30 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
JP6718823B2 (ja) * 2014-05-06 2020-07-08 ジーティーエックス・インコーポレイテッド 癌の処置のための化合物
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10226448B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024004A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024021A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
WO2017023975A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10392383B2 (en) 2015-08-03 2019-08-27 Samumed, Llc 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023988A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023993A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
AR106595A1 (es) 2015-11-06 2018-01-31 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
US10899757B2 (en) 2015-11-06 2021-01-26 Samumed, Llc 2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof
ES2833955T3 (es) 2016-01-05 2021-06-16 Incyte Corp Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma
CN108699080B (zh) 2016-02-23 2021-05-14 辉瑞公司 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
MD3464285T2 (ro) 2016-06-01 2023-01-31 Biosplice Therapeutics Inc Procedeu pentru prepararea N-(5-(3-(7-(3-fluorfenil)-3H-imidazo[4,5-c]piridin-2-il)-1H-indazol-5-il)piridin-3-il)-3-metilbutanamidei
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
MX2019004616A (es) 2016-10-21 2019-11-21 Samumed Llc Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
MA46696A (fr) 2016-11-07 2019-09-11 Samumed Llc Formulations injectables à dose unique prêtes à l'emploi
EP4006034A1 (de) 2017-10-18 2022-06-01 Incyte Corporation Durch tertiäre hydroxygruppen substituierte kondensierte imidazolderivate als pi3k-gamma-inhibitoren
MA53561A (fr) 2018-09-05 2022-05-11 Incyte Corp Formes cristallines d'un inhibiteur de phosphoinositide 3-kinase (pi3k)
KR20210060556A (ko) 2018-09-18 2021-05-26 니캉 테라퓨틱스 인코포레이티드 Src 호몰로지-2 포스파타아제 억제제로서의 3-치환된 헤테로아릴 유도체
WO2020142559A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
SG11202106304RA (en) 2018-12-31 2021-07-29 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction
WO2020198351A1 (en) * 2019-03-25 2020-10-01 The Trustees Of Columbia University In The City Of New York Selective foxo inhibitors for treatment of diabetes and other disorders related to impaired pancreatic function
CN112206309A (zh) * 2019-07-11 2021-01-12 滨州医学院 双靶点血管抑制剂在制备预防或治疗纤维化药物中的用途
CR20220316A (es) 2019-12-06 2022-10-07 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
EP4077316A1 (de) 2019-12-20 2022-10-26 Pfizer Inc. Benzimidazolderivate
WO2022066938A1 (en) * 2020-09-24 2022-03-31 Forkhead Biotherapeutics, Inc. Agents for the treatment of diseases by inhibition of foxo1
AR126073A1 (es) 2021-06-04 2023-09-06 Vertex Pharma N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio
CN114478511B (zh) * 2022-02-24 2023-06-20 中国药科大学 苯并恶唑类化合物及其制备方法、药物组合物和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549754A (en) * 1969-04-21 1970-12-22 Merck & Co Inc Combination of 2-substituted benzimidazoles and substituted phenothiazines in the treatment of helminthiasis
US3711608A (en) * 1971-04-13 1973-01-16 Merck & Co Inc The treatment of pain, fever and inflammation with benzimidazoles
DE2130029A1 (de) * 1971-06-18 1972-12-21 Bayer Ag Verfahren zur Herstellung von 2-[Pyrazolyl-(1)]-benzimidazolen
DE2130030A1 (de) * 1971-06-18 1972-12-21 Bayer Ag Fungizide und bakterizide Mittel
BE793501A (fr) * 1971-12-31 1973-06-29 Ciba Geigy Composes heterocycliques et produits phytopharmaceutiques qui en contiennent
DE2453210C3 (de) * 1974-11-09 1979-11-22 Bayer Ag, 5090 Leverkusen Bekämpfung von Pilzen der Gattung Hehmnthosporium mit Dimethyipyrazolylbenzimidazol
AU6966696A (en) * 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
DE69810938T2 (de) * 1997-04-11 2003-11-06 Grelan Pharmaceutical Co Pyrazolderivate und sie enthaltende cox-inhibitoren
ME00370B (me) * 1999-06-23 2011-05-10 Sanofi Aventis Deutschland SUPSTITUISANI BENZIMIDAZOLl
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
US6897208B2 (en) * 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03035644A1 *

Also Published As

Publication number Publication date
JP2005509639A (ja) 2005-04-14
FR2831536A1 (fr) 2003-05-02
MXPA04003381A (es) 2004-06-18
WO2003035644A1 (fr) 2003-05-01
US20080125418A1 (en) 2008-05-29
US20050009894A1 (en) 2005-01-13
JP2009167219A (ja) 2009-07-30
JP4377228B2 (ja) 2009-12-02
CA2466813A1 (fr) 2003-05-01

Similar Documents

Publication Publication Date Title
WO2003035644A1 (fr) Derives de benzimidazoles et_leur utilisation comme inhibiteurs de proteine kinase kdr
CA2695628C (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
FR2928645A1 (fr) Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2006003276A1 (fr) Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
CA2449771A1 (fr) Derives de benzothienyle ou d'indole et leur utilisation comme inhibiteurs de proteines prenyl transferase
FR2917735A1 (fr) Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
CA2730959A1 (fr) Nouveaux derives triazolo[4,3-a]pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
CA2730749A1 (fr) Nouveaux derives imidazo[1,2-a]pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment commeinhibiteurs de met
FR2911137A1 (fr) Nouveaux derives de 2,4-dianilinopyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
EP2041119B1 (de) Pyrazolylbenzimidazolderivate, diese enthaltende zusammensetzungen und ihre verwendung
CA2755660A1 (fr) Derives d'indazole inhibiteurs d'hsp90, compositions les contenant et utilisation
FR2907120A1 (fr) Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7
EP2448924A2 (de) Pyrazolderivate, ihre herstellung und therapeutische verwendung
EP1633738A2 (de) Neue indolderivate, verfahren zu deren herstellung in form von medikamenten, pharmazeutische zusammensetzungen und insbesondere kdr-inhibitoren
FR2932484A1 (fr) Nouveaux derives de pyrroloindole inhibiteurs d'hsp90, compositions les contenant et utilisation
FR2831537A1 (fr) Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation
WO2008049994A1 (fr) Nouveaux derives du fluorene, compositions les contenant et utilisation comme inhibiteurs de la proteine chpaerone hsp90
FR2856062A1 (fr) Derives 3-guanidinocarbonyl-heterocycle, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
FR2943341A1 (fr) Nouveaux derives d'indazole inhibiteurs d'hsp90,compositions les contenant et utilisation
WO2001009124A1 (fr) Derives 8-carbonyl chromanes, leur preparation et leur utilisation en therapique
FR2955323A1 (fr) Nouveaux derives d'indazole inhibiteurs d'hsp90, compositions les contenant et utilisation
WO2001009112A1 (fr) Nouveaux derives 8-carbonyl chromanes, leur preparation et leur utilisation en therapeutique
FR2929613A1 (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040526

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RBV Designated contracting states (corrected)

Designated state(s): DE ES FR GB IT

17Q First examination report despatched

Effective date: 20050311

17Q First examination report despatched

Effective date: 20050311

17Q First examination report despatched

Effective date: 20050311

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100518